NASDAQ$UFPT

UFP Technologies Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

UFP Technologies reported record results for the second quarter of 2024, driven by sales growth and margin expansion.

UFP Technologies announced record Q2 results with a 10.1% increase in sales, a gross margin growth to 30.0%, and a 14.0% increase in net income. The company also completed three acquisitions expected to add $90 million in revenue and $20 million in EBITDA.

  • Sales increased by 10.1% compared to the same quarter last year, reaching $110.2 million.
  • Net income grew by 14.0% to $13.6 million, or $1.75 per diluted share.
  • Gross margins improved to 30.0% due to manufacturing efficiency and cost control.
  • Three acquisitions were completed, expected to add $90 million in revenue and $20 million in EBITDA.

Headline financials

Total Revenue

$110M

Previous: $100M+10.1%
EPS

$1.75

Previous: $1.55+12.9%
Gross Margin

30.0%

No prior period
Adjusted SG&A %

11.6%

No prior period
Adjusted EBITDA

$23.9M

No prior period
Capital Expenditures

-$4.5M

Previous: -$4.95M+9.0%
Free Cash Flow

$9.05M

Previous: $6.93M+30.5%
Net Income

$13.6M

Previous: $11.9M+14.0%
Operating Income

$18M

Previous: $17M+5.3%
Gross Profit

$33M

Previous: $29.6M+11.4%
Cash & Equivalents

$16.7M

Previous: $5.29M+216.2%
Total Assets

$422M

Previous: $398M+6.1%
Stock-Based Comp

$1.74M

Previous: $1.2M+45.0%

Revenue & EPS history

UFP Technologies · Revenue · Quarterly

$110M

Q2 2024+10.1%vs Q2 2023
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Revenue by segment

UFP Technologies · $6.8M total across 1 segment · Q3 2023

  • Medical
    $6.8M

Forward guidance

UFP Technologies anticipates future growth through recent acquisitions, a strong product development pipeline, and a new $275 million line of credit.

Tailwinds

  • Expected synergies from recent acquisitions.
  • Strong pipeline of product development business.
  • Additional acquisition opportunities.
  • New $275 million line of credit.
  • Strength in robotic surgery and infection prevention markets.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+2.7%

Avg return

Earnings day

+3.1%

Avg return

5 days after

+5.5%

Avg return

30 days after

66%

43 / 65 earnings

Positive

+24.0%

Q1 2024

Best reaction

-11.6%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.2%-1.0%+1.1%
Q4 2025+0.3%-15.1%-21.2%
Q3 2025+12.2%+13.6%+8.6%
Q1 2025+11.2%+19.8%+23.6%
Q4 2024+9.4%-5.5%-15.7%
Q3 2024+23.8%+24.2%+4.5%
Q2 2024+2.8%-5.4%+7.7%
Q1 2024+24.0%+24.5%+26.4%
Q4 2023+10.5%+11.3%+26.2%
Q3 2023-11.6%-8.0%+6.9%
Q2 2023-5.5%-6.3%-9.7%
Q1 2023+5.8%+2.0%+13.9%
Q4 2022+10.8%+2.9%+16.5%
Q3 2022+16.4%+21.5%+31.6%
Q2 2022+11.2%+11.1%+14.1%
Q1 2022+5.9%+3.1%+14.2%
Q4 2021-1.0%-11.1%+1.3%
Q3 2021+4.1%+6.8%+7.6%
Q2 2021+9.6%+12.5%+14.8%
Q1 2021+8.1%+8.8%+15.4%
Q4 2020+1.4%-7.8%-0.7%
Q3 2020+13.2%+18.9%+25.0%
Q2 2020+3.7%+2.5%-6.4%
Q1 2020+1.3%+7.1%+10.0%
Q4 2019+3.0%-4.2%-28.6%
Q3 2019-0.2%+1.3%+7.7%
Q2 2019+2.6%-1.4%-2.2%
Q1 2019+2.8%+3.6%+5.0%
Q4 2018-1.4%-0.2%+8.6%
Q3 2018-0.8%-1.8%+5.1%
Q2 2018+2.7%+10.2%+7.6%
Q1 2018-0.6%-3.2%-6.2%
Q4 2017-3.3%-1.4%+3.7%
Q3 2017-10.1%-11.1%-9.0%
Q2 2017-3.3%-3.8%-8.0%
Q1 2017+1.7%+1.1%+4.9%
Q4 2016+0.4%+1.2%+5.7%
Q3 2016-4.6%-3.5%-4.6%
Q2 2016+3.3%+2.9%+7.5%
Q1 2016+1.3%
Q4 2015+5.6%
Q3 2015-0.6%
Q2 2015+12.7%
Q1 2015-2.7%
Q4 2014-7.5%
Q3 2014+0.9%
Q2 2014-2.1%
Q1 2014-1.2%
Q4 2013+0.1%
Q3 2013-0.9%
Q2 2013+1.4%
Q1 2013-3.4%
Q4 2012-0.6%
Q3 2012-2.5%
Q2 2012+1.3%
Q1 2011+2.5%
Q1 2012+0.6%
Q4 2009-3.0%
Q4 2011-3.0%
Q3 2010+2.6%
Q3 2011+2.6%
Q4 2010+1.3%
Q2 2010+1.3%
Q2 2011+1.3%
Q1 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro